Metabolic reprogramming and resistance to regulated cell death (RCD) are central features of the tumor microenvironment (TME) that drive therapeutic failure. Emerging evidence indicates that neurotransmitter signaling networks-including glutamate, dopamine, 5-hydroxytryptamine (5-HT), and norepinephrine-extend beyond n...
Yi-Ming Yan, Hao-Jie Sun, Zi-Qiang Liu et al.· Pharmacological Research· 0 citations
B7 homolog 3 protein (B7-H3, also known as CD276) has emerged as a promising immune checkpoint target because of its high expression in solid tumors, limited presence in normal tissues and roles in immune evasion and tumor progression. This review focuses on the biological and therapeutic relevance of B7-H3 in lung and...
Soorya Suresh, Surabhi Maurya, Kajal Singh et al.· Drug Discovery Today· 0 citations
Overall, immunotherapy resistance in urological malignancies is a multifactorial and dynamic process involving tumor, microenvironmental, and host determinants, and a comprehensive, mechanism-driven approach integrating biomarker-guided strategies and combination therapies is essential to improve clinical outcomes and...
Pin-Ying Wang, Bohan Zhang, Yaxing Shi et al.· Journal of Advanced Research· 1 citation
It is suggested that TRIM27 confers ferroptosis resistance via facilitating K48-linked ubiquitination and subsequent proteasomal degradation of ACSL4 and developed TRIM27-Cas9-loaded EVs with robust editing efficiency.
Jie Wen, Zhihui Wang, Zhirui Zeng et al.· Cell Death and Differentiati...· 1 citation
Advances in antibody-drug conjugates, cancer vaccines, and adoptive cellular therapies are discussed as promising strategies that combine targeted cytotoxicity with immune activation.
Vivek Uttam, Sia Daffara, Sandeep Singh et al.· Biochemical Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
